|
|
|
| Effect of Thymalfasin Combined with High-flow Nasal Cannula Oxygen Therapy in the Treatment of Severe Pneumonia Complicated with Respiratory Failure |
| YUE Hongyun, HAN Jingxu, LI Shiyuan, LAN Jie |
| First-author's address: Shijiazhuang People's Hospital, Shijiazhuang 050000, China |
|
|
|
|
Abstract Objective: To explore the effect of Thymalfasin combined with high-flow nasal cannula oxygen therapy (HFNC) in the treatment of severe pneumonia complicated with respiratory failure. Method: A total of 96 patients with severe pneumonia complicated with respiratory failure who were admitted to Shijiazhuang People's Hospital from January 2021 to July 2022 were taken as the research objects and divided into the control group and the observation group according to the random number table method, with 48 cases in each group. The control group was treated with HFNC on the basis of routine treatment, and the observation group was treated with Thymalfasin on the basis of control group. The clinical efficacy, before and after treatment of levels of inflammation mediators and arterial blood gas indicators were observed in the two groups. Result: The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), high mobility group box proteinl (HMGB-1), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). After treatment, the arterial partial pressure of oxygen (PaO2) and arterial oxygen saturation (SaO2) in the observation group were higher than those in the control group, the differences were statistically significant (P<0.05). Conclusion: Thymalfasin combined with HFNC in the treatment of severe pneumonia complicated with respiratory failure can improve clinical efficacy, reduce inflammatory reaction and improve blood oxygen content.
|
|
Received: 20 April 2023
|
|
|
|
|
|
|
